Insmed | INSM - Selling And Administration Expenses

Stock Price
163.30
Daily Change
-1.61 -0.98%
Monthly
4.47%
Yearly
101.46%
Q1 Forecast
159.80

Insmed reported $212.48M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
BioMarin Pharmaceutical USD 223.42M 8.86M Sep/2025
Cytokinetics USD 158.75M 93.03M Sep/2025
DBV Technologies USD 3.63M 3.18M Sep/2025
Gilead Sciences USD 1.78B 425M Dec/2025
Heron Therapeutics USD 23.34M 4.18M Sep/2024
Insmed USD 212.48M 26.11M Dec/2025
Novartis USD 3.3B 137M Sep/2025
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Sarepta Therapeutics USD 77.11M 7.22M Sep/2025
Ultragenyx Pharmaceutical USD 89M 2.38M Dec/2025
Vertex Pharmaceuticals USD 487M 41.9M Dec/2025